Table 1.
all PAH patients |
Patients with RV pressure trace analysis |
p value* | ||
---|---|---|---|---|
N=140 | PAH n=84 | Controls n=22 | ||
Age years | 55 ± 16 | 55 ± 16 | 58 ± 14 | 0.518 |
Sex % female | 66 | 64 | 64 | 1.00 |
Aetiology % (n) | ||||
IPAH/FPAP | 53.6 (75) | 63 (53) | ||
CTDPH | 37.9 (53) | 31 (26) | ||
POPH | 6.4 (9) | 5 (4) | ||
HIV | 1.4 (2) | 0 | ||
CHD | 0.7 (1) | 1 (1) | ||
Therapy % (n) | ||||
PDE5i | 51.4 (72) | 59.5 (50) | ||
ERA | 35 (49) | 28.6 (24) | ||
Prostanoid | 5.0 (7) | 1.2 (1) | ||
CCB | 2.1 (3) | 1.2 (1) | ||
Dual | 6.4 (9) | 9.5 (8) | ||
mPAP mmHg | 48 ± 13 | 50 ± 13 | 18 ± 4 | <0.001 |
RAP mmHg | 7 ± 6 | 8 ± 6 | 3 ± 2 | <0.001 |
PVR Wood units | 11.8 ± 5.8 | 12.2 ± 5.9 | 2.1 ± 0.9 | <0.001 |
CI L/min/m2 | 2.2 ± 0.6 | 2.2 ± 0.7 | 3.0 ± 0.8 | <0.001 |
SV/PP mL/mmHg | 1.03 ± 0.5(138) | 0.99 ± 0.4(82) | 3.7 ± 1.5 | <0.001 |
RVEF % | 36 ± 15 | 33 ± 13 | 58 ± 14 | <0.001 |
SVI mL/m2 | 31 ± 10 | 30 ± 10 | 43 ± 20 | <0.001 |
RVEDVI mL/m2 | 92 ± 26 | 94 ± 28 | 74 ± 25 | 0.004 |
RVESVI mL/m2 | 61 ± 27 | 64 ± 28 | 31 ± 16 | <0.001 |
RVMI g/m2 | 52 ± 19 | 53 ± 18 | 36 ± 16 | <0.001 |
6MWD m | 305 ± 117(77) | 404 ± 116(21) | 0.001 | |
NTproBNP pg/mL | 1140 (96 – 3577)(75) |
182 (45 – 243) (12) |
<0.001 |
Data presented as % (n), mean±sd or median (IQR) unless otherwise stated.
p value comparison between controls and subgroup 84 PAH patients.
PAH: pulmonary arterial hypertension; RV: right ventricle; IPAH: idiopathic PAH; FPAP: familial PAH; CTDPH: connective tissue disease associated PH; POPH: portopulmonary hypertension; CHD: congenital heart disease associated PH; PDE5i: phosphodiesterase type 5 inhibitor; ERA: endothelial receptor antagonist; CCB: calcium channel blocker; mPAP: mean pulmonary artery pressure; RAP: right atrial pressure; PVR: pulmonary vascular resistance; CI: cardiac index; SV/PP: compliance, ratio stroke volume/pulse pressure; RVEF: RV ejection fraction; SVI: stroke volume index; RVEDVI: RV end diastolic volume index; RVESVI: RV end systolic volume index; RVMI: RV mass index; 6MWD: six minute walk distance; NTproBNP: N terminal pro-brain natriuretic peptide.